# Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
Canonical URL: https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-fda-breakthrough-therapy-designation-for-nomlabofusp-in-fa-and-reiterates-planned-bla-submission-in-june-2026
Ticker: LRMR
Company: Larimar Therapeutics
Source: Larimar Therapeutics
Published: 2026-02-24 12:00 EST
Original Source URL: https://investors.larimartx.com
## Summary

Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study FDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission

## Article Body
Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA’s review of available clinical data from open label study FDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission
## Recent Company News
- 2026-05-14 11:00 EST — [Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-first-quarter-2026-financial-and-business-update) — Source: Larimar Therapeutics
- 2026-04-30 20:05 EST — [Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-publishes-cross-species-findings-supporting-skin-as-a-surrogate-for-the-measurement-of-frataxin-in-tissues-clinically-relevant-to-friedreich-s-ataxia) — Source: Larimar Therapeutics
- 2026-03-19 11:00 EST — [Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Larimar Therapeutics
- 2026-03-04 21:05 EST — [Larimar Therapeutics to Participate in Upcoming Investor Conferences in March](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-to-participate-in-upcoming-investor-conferences-in-march) — Source: Larimar Therapeutics
- 2026-02-26 01:59 EST — [Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering](https://biopharmsignal.com/news/LRMR/larimar-therapeutics-announces-pricing-of-upsized-100-million-underwritten-public-offering) — Source: Larimar Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)